Kintor Pharma IPO Initiation: To Screen, or Not to Screen?
Kintor Pharmaceutical (1762178D CH) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers...
280 Views
Kintor Pharma (开拓药业) Pre-IPO: Post Hearing Updates and Efficacy of Reference Products
Kintor was founded by Chinese academic researchers returning from overseas. It has two main drugs, proxalutamide which targets prostate cancer and...
332 Views
ECM Weekly (29 Mar 2020) - Wuxi AppTec, Kintor Pharma, Softbank Group-Driven Placements and More!
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. We...
358 Views
Kintor Pharma (开拓药业) Pre-IPO: Thoughts on Valuation
Kintor was founded by Chinese academic researchers returning from overseas. It has two main drugs, proxalutamide which targets prostate cancer and...
719 Views
Kintor Pharma (开拓药业) Pre-IPO: Interesting Prostate Cancer Drug but Low in Core Assets
Kintor was founded by Chinese academic researchers returning from overseas. It has two main drugs, proxalutamide which targets prostate cancer and...
554 Views